Ultragenyx Pharmaceu (RARE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 480,693 | 112,250 | 213,584 | 72,575 | 102,059 |
| Marketable Securities | 283,128 | 299,830 | 363,625 | 369,519 | 449,922 |
| Receivables | 105,982 | 100,253 | 73,390 | 79,263 | 70,523 |
| Inventories | 40,137 | 35,907 | 33,969 | 31,802 | 28,256 |
| TOTAL | $964,640 | $595,967 | $732,184 | $599,188 | $702,137 |
| Non-Current Assets | |||||
| PPE Net | 278,707 | 285,111 | 290,566 | 296,811 | 288,990 |
| Investments And Advances | 110,669 | 156,581 | 199,901 | 86,110 | 71,829 |
| Intangibles | 210,649 | 209,451 | 210,677 | 201,708 | 202,643 |
| Other Non-Current Assets | 53,772 | 59,970 | 57,685 | 54,323 | 45,711 |
| TOTAL | $653,797 | $711,113 | $758,829 | $638,952 | $609,173 |
| Total Assets | $1,618,437 | $1,307,080 | $1,491,013 | $1,238,140 | $1,311,310 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 59,807 | 40,972 | 42,114 | 33,357 | 42,115 |
| Accrued Expenses | 154,421 | 149,133 | 196,486 | 178,622 | 167,656 |
| Other current liabilities | 46,921 | 42,689 | 29,242 | 29,932 | 23,724 |
| TOTAL | $272,866 | $245,575 | $280,437 | $253,978 | $244,379 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 883,095 | 891,183 | 905,104 | 920,781 | 906,234 |
| TOTAL | $913,153 | $921,241 | $935,162 | $952,448 | $937,901 |
| Total Liabilities | $1,186,019 | $1,166,816 | $1,215,599 | $1,206,426 | $1,182,280 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 92,165 | 83,133 | 82,336 | 82,114 | 71,489 |
| Common Shares | 92 | 83 | 82 | 72 | 71 |
| Retained earnings | -3,689,943 | -3,558,345 | -3,387,661 | -3,264,471 | -3,104,822 |
| Other shareholders' equity | 1,905 | 2,569 | 647 | -2,244 | -3,098 |
| TOTAL | $432,418 | $140,264 | $275,414 | $31,714 | $129,030 |
| Total Liabilities And Equity | $1,618,437 | $1,307,080 | $1,491,013 | $1,238,140 | $1,311,310 |